Genentech, Elan Deals Limiting?
Biogen Idec Officially Hunts Buyer; Icahn, Pharma Hover
By Randall Osborne
Tuesday, October 16, 2007
Biogen Idec Inc.'s confirmation of months-long buzz that the company is talking with potential buyers boosted the stock and started onlookers speculating about advantages, drawbacks and hurdles - as well as the timing of a potential deal, given worries that still linger over Tysabri, and given Biogen's possibly value-stimulating pipeline news in the year ahead. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.